一、 一种提高β-烟酰胺单核苷酸结晶粉末松堆密度的方法 厦门金达威集团股份有限公司（以下简称公司）控股子公司江苏诚信药业有 限公司，公司及公司全资子公司内蒙古金达威药业有限公司、全资孙公司金达威 生物技术（江苏）有限公司，公司及公司全资子公司厦门金达威维生素有限公司 近日合计收到国家知识产权局颁发的 3 件发明专利证书，具体情况如下： 发明名称：一种提高β-烟酰胺单核苷酸结晶粉末松堆密度的方法 证券代码：002626 证券简称：金达威 公告编号：2024-042 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 专利号：ZL 2021 1 0626728.5 专利申请日：2021 年 6 月 4 日 专利权人：天津大学;江苏诚信药业有限公司 专利权期限：二十年 证书号：第 6931598 号 授权公告日：2024 年 4 月 23 日 本发明涉及一种提高β-烟酰胺单核苷酸结晶粉末松堆密度的方法。本发明 选用的溶剂对健康的危害性低，加之操作简单，回收率高于 90%，从而有利于实 现工业化生产。 二、 采用微生 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 743,170,048.30, a decrease of 5.99% compared to CNY 790,491,584.29 in the same period last year[12] - Net profit attributable to shareholders for Q1 2024 was CNY 70,793,791.49, down 18.58% from CNY 86,951,244.72 in the previous year[12] - Total operating revenue for Q1 2024 was ¥743,170,048.30, a decrease of 5.95% from ¥790,491,584.29 in the previous period[51] - The net profit for the first quarter was ¥70,882,477.49, a decrease of 15.3% compared to ¥83,634,871.69 in the previous year[52] - The company reported a total comprehensive income of ¥76,136,969.89, compared to ¥59,202,866.61 in the same period last year, indicating an increase of 28.6%[54] Cash Flow and Financial Position - The company's cash flow from operating activities decreased significantly by 98.32%, amounting to CNY 3,950,059.02 compared to CNY 235,416,458.25 in the same period last year[12] - The cash flow from operating activities showed a net increase of ¥3,950,059.02, significantly lower than the previous year's ¥235,416,458.25[57] - The cash and cash equivalents at the end of the period totaled ¥736,877,073.28, a decrease from ¥800,705,490.96 at the end of the previous year[60] - The company incurred a total of ¥694,317,278.84 in cash outflows from operating activities, compared to ¥538,255,431.18 in the previous year, representing an increase of 29%[57] - The net cash flow from financing activities was ¥155,799,164.08, an increase from ¥96,359,432.55 in the previous year[60] Assets and Liabilities - The total assets as of March 31, 2024, were CNY 5,561,221,522.45, reflecting a 3.88% increase from CNY 5,353,392,042.82 at the end of the previous year[12] - Total assets as of the reporting date were ¥5,561,221,522.45, an increase from ¥5,353,392,042.82 in the previous period[46] - Total liabilities increased to ¥1,548,593,807.05 from ¥1,416,901,298.61, representing a rise of 9.28%[45] - Current liabilities totaled ¥833,906,555.04, an increase from ¥664,032,640.34, marking a rise of 25.5%[45] - The company's total equity increased to ¥4,012,627,715.40 from ¥3,936,490,744.21, reflecting a growth of 1.93%[46] Investments and Expenses - The company’s investment income from joint ventures and associates decreased by 60.26% to CNY 869,250.55 from CNY 2,187,471.66[5] - Research and development expenses increased to ¥16,083,859.74, up 10.63% from ¥14,539,086.42 in the previous period[51] - The company reported a significant reduction in financial expenses by 84.19%, totaling CNY 1,853,819.67 compared to CNY 11,724,795.12 in the previous year[5] - The company reported a decrease in financial expenses to ¥1,853,819.67 from ¥11,724,795.12, a reduction of approximately 84.16%[51] - The total impairment losses for assets were ¥1,470,118.89, a decrease from ¥2,411,251.70 in the previous year, indicating a reduction of 39%[52] Operational Incidents and Acquisitions - The company reported a significant incident at its facility, resulting in 3 fatalities and 3 injuries, which may impact operational capacity[30] - The company announced the acquisition of 100% equity in Activ Nutritional, LLC from Viactiv Nutritionals, Inc. for $1.7 million, pending regulatory approvals[33] - The company holds a 96.11% stake in its U.S. subsidiary, Doctor's Best Inc., which is involved in the acquisition mentioned above[33] - The company has entered a recovery phase following the incident at its facility, indicating a focus on resuming normal operations[30] Shareholder Information - The company confirmed that there are no non-recurring gains classified as recurring gains in its financial statements[25] - The company has not identified any related party transactions among its top shareholders[27] - The total number of shares held by the top 10 shareholders includes significant stakes from Xiamen Jindawei Investment Co., Ltd. and Zhongmu Industrial Co., Ltd.[27]

证券代码：002626 证券简称：金达威 公告编号：2024-041 厦门金达威集团股份有限公司 关于参加厦门辖区上市公司 2023 年年报业绩说明会暨 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，厦门金达威集团股份有限公司（以下简 称公司）将参加由厦门证监局、厦门上市公司协会与深圳市全景网络有限公司联 合举办的“厦门辖区上市公司 2023 年年报业绩说明会暨投资者网上集体接待日 活动”，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录“全景路演”网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP 参与 本次互动交流，活动时间为 2024年5月16 日（周四）14:00-17:00。届时公司董 事长兼总经理江斌先生、董事、副总经理兼财务总监洪航先生、独立董事王肖健 先生、副总经理兼董事会秘书洪彦女士将在线就公司 2023年度业绩、公司治理、 发展战略、经营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交 ...

Financial Performance - The company's operating revenue for the reporting period was approximately CNY 790.49 million, showing a slight increase compared to the previous quarter's CNY 761.23 million[5]. - Net profit attributable to shareholders was CNY 86.95 million, a decrease from CNY 97.07 million in the previous quarter[5]. - The net cash flow from operating activities reached CNY 235.42 million, up from CNY 206.36 million in the previous quarter[5]. - The company's total revenue for 2023 reached ¥3,102,580,918.31, representing a year-on-year increase of 3.10% compared to ¥3,009,229,135.39 in 2022[80]. - The cost of sales increased by 8.58% to ¥1,944,485,343.22 from ¥1,790,843,728.24 in the previous year[80]. - The net cash flow from operating activities decreased by 5.25% to ¥658,652,838.62, down from ¥695,121,586.16 in 2022[80]. - The revenue from the nutrition and health products segment was ¥3,023,706,681.23, accounting for 97.46% of total revenue, with a year-on-year growth of 3.02%[86]. - The sales volume of nutrition and health products decreased by 12.06% to 3,199,290.53 kg from 3,637,987.91 kg in 2022[87]. - The gross profit margin for the nutrition and health products segment was 37.21%, reflecting a decrease of 3.02% compared to the previous year[86]. - The company reported a significant decline in revenue from its vitamin segment, with a decrease of 52.20% year-over-year[129]. Market Trends and Industry Insights - The global health consumption market size reached USD 321.9 billion in 2023, with a year-on-year growth of 5.81%[15]. - The feed additive industry in China saw a total output value of CNY 1,223.42 billion in 2023, growing by 6.5% year-on-year[19]. - The vitamin production capacity in China has entered a new expansion phase, with the country now accounting for over 70% of global vitamin production[44]. - The market for DHA derived from algae oil is rapidly growing, with advantages in food safety and quality control[47]. Product Development and Innovation - The company achieved record sales of coenzyme Q10 raw materials, with production and sales hitting historical highs[34]. - The company is expanding its product line with new projects, including an annual production of 100 tons of adenosylmethionine and 1,000 tons of astaxanthin, which are nearing completion[34]. - The company has a strong research and innovation capability, continuously optimizing production processes to reduce costs and improve product efficacy and safety[45]. - The company utilizes biocatalysis technology for the production of NMN raw materials, ensuring advanced and reliable production processes[46]. - The company is focusing on technological innovation and product development to strengthen its market competitiveness[54]. Sales and Distribution - The company employs a direct sales model combined with distribution, with no restrictions on the number of distributors or sales areas[38]. - The company reported a total sales revenue of 493,554,910.90 CNY from its top distributor, accounting for 15.91% of total sales[40]. - The online sales of nutrition and health products increased by 16.55% to ¥992,397,839.82, representing 31.99% of total revenue[86]. - The company has established 9 health food sales stores in major business districts in Singapore, utilizing a direct sales model[60]. Research and Development - The company held 182 authorized patents as of December 31, 2023, including 176 in China and 6 in the United States[68]. - The company's total R&D expenditure was CNY 66,594,017.88, representing a decrease of 7.33% from CNY 71,857,719.17 in the previous year[113]. - The number of R&D personnel increased by 15.42% to 232, with the proportion of R&D personnel in the company rising to 10.91%[93]. - Research and development expenses decreased by 19.01% to ¥58,198,995.12 from ¥71,857,719.17 in the previous year[92]. Financial Position and Cash Flow - The company's total operating cash inflow for 2023 was CNY 3,188,829,940.57, a slight increase of 0.33% compared to CNY 3,178,349,626.47 in 2022[103]. - The total cash inflow from financing activities increased by 22.98% to CNY 596,410,000.00, while cash outflow decreased by 24.72% to CNY 781,592,355.33[103]. - The net increase in cash and cash equivalents rose significantly by 162.37% to CNY 53,901,676.90, compared to a decrease of CNY 86,423,560.04 in 2022[116]. - The company's total liabilities included long-term borrowings of CNY 438,540,000.00, which increased significantly from CNY 214,850,000.00 in 2022[106]. Challenges and Risks - The company faces increasing competition in the nutritional health food market, which may impact its operational performance if competitiveness is not enhanced[135]. - Fluctuations in product prices due to raw material costs and market supply dynamics could affect the company's financial stability[137]. - The company acknowledges risks related to foreign subsidiaries, including political, legal, and operational risks that could affect investment outcomes[155]. - The company recognizes the potential increase in environmental protection costs due to stricter regulations, which may impact profitability[147]. Strategic Initiatives - The company is focused on expanding its market presence through new product development and leveraging new media and technology[43]. - The company plans to distribute a cash dividend of CNY 2 per 10 shares, based on a total of CNY 609.93 million[158]. - The company is exploring potential acquisitions to enhance its technological capabilities and market reach[195]. - A new strategic partnership was established with a leading environmental technology firm to co-develop advanced treatment solutions[195].

证券代码：002626 证券简称：金达威 公告编号：2024-030 | | | | | | | | | 冻 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 结 | | | | | | | | | | | 数 | | | | | | | | | | | 量 | | | 金达威投 | 211,712,732 | 34.71% | 92,191,500 | 43.55% | 15.11% | 0 | 0 | 0 | 0 | | 资 | | | | | | | | | | 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦 门金达威投资有限公司（以下简称金达威投资）将其所持有的本公司部分股票 解除质押的通知，现将有关事项公告如下： 一、 股东股份解除质押的基本情况 1. 本次解除质押基本情况 | | 是否为 控股股 | 本次解除 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 东或第 | 质押 ...

证券代码：002626 证券简称：金达威 公告编号：2024-029 截至公告披露日，上述股东所持质押股份情况如下： 股东 名称 持股数量 持股比 例 本次质押 前质押股 份数量 本次质押 后质押股 份数量 占其所 持股份 比例 占公司 总股本 比例 已质押股 份情况 未质押股 份情况 已 质 押 股 份 限 占 已 质 押 股 份 未质 押股 份限 售和 冻结 数量 占 未 质 押 股 份 | | | | | | | | 售 | 比 | | 比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 和 | 例 | | 例 | | | | | | | | | 冻 | | | | | | | | | | | | 结 | | | | | | | | | | | | 数 | | | | | | | | | | | | 量 | | | | | 金达 | | | | | | | | | | | | 威投 | 211,712,732 | 34.71% | 90,091,500 | 103,491,500 ...

证券代码：002626 证券简称：金达威 公告编号：2024-028 厦门金达威集团股份有限公司 专利权人：江苏诚信药业有限公司;厦门金达威集团股份有限公司 专利权期限：二十年 证书号：第 6920785 号 授权公告日：2024 年 4 月 19 日 本发明提供一种生物酶催化合成 L-肌肽的方法。本发明通过利用生物酶和 微孔聚合物的共同作用，使得 L-组氨酸与 β-丙氨酸可以经过一步反应得到 L-肌 肽，并且具有高的产物收率以及高的产物纯度。 上述专利的取得不会对公司生产经营产生重大影响，但有利于公司的技术创 新，充分发挥自主知识产权优势，进一步完善知识产权保护体系，增强公司的核 心竞争力。 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）及公司控股子公司江苏诚信 药业有限公司近日收到国家知识产权局颁发的 1 件发明专利证书，具体情况如 下： 发明名称：一种生物酶催化合成 L-肌肽的方法 专利号：ZL 2022 1 1294445.6 专利申请日：2022 年 10 月 21 日 特此公告 ...

证券代码：002626 证券简称：金达威 公告编号：2024-027 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 专利号：ZL 2020 1 1613569.7 专利申请日：2020 年 12 月 30 日 专利权人：江苏诚信药业有限公司 专利权期限：二十年 证书号：第 6884206 号 授权公告日：2024 年 4 月 9 日 厦门金达威集团股份有限公司（以下简称公司）控股子公司江苏诚信药业有 限公司，公司及全资子公司内蒙古金达威药业有限公司、全资孙公司金达威生物 技术（江苏）有限公司近日分别收到国家知识产权局颁发的 1 件发明专利证书， 具体情况如下： (一)一种烟酰胺腺嘌呤二核苷酸的制备方法 发明名称：一种烟酰胺腺嘌呤二核苷酸的制备方法 授权公告日：2024 年 04 月 09 日 本发明提供一种烟酰胺腺嘌呤二核苷酸的制备方法。使用本发明的制备方法 能够提高产物 NAD+的生成率，并降低反应后处理的难度。 (二)一种以改性硅藻土为载体的固定化全细胞催化制备 β-烟酰胺单核苷酸 的方法 发明名称 ...

关于对厦门金达威集团股份有限公司 及相关责任人的监管函 公司部监管函〔2024〕第 64 号 厦门金达威集团股份有限公司董事会及相关责任人： 2024 年 4 月 8 日，你公司发布的《关于前期财务信息更正 的公告》显示，经公司自查，公司 2020 年和 2021 年年度报告中 加权平均净资产收益率计算错误，公司 2022 年年度报告中加权 平均净资产收益率、基本每股收益和稀释每股收益计算错误，公 司在公告中更正了相关数据。 你公司的上述行为违反了本所《股票上市规则（2023 年修 订）》第 1.4 条、第 2.1.1 条的规定。你公司财务总监洪航未能 勤勉尽责，违反了本所《股票上市规则（2023 年修订）》第 1.4 条、第 2.1.1 条、第 4.3.1 条的规定，对此负有责任。 本所希望你公司及全体董事、监事、高级管理人员认真吸取 教训，并提醒你公司及全体董事、监事、高级管理人员严格遵守 《证券法》《公司法》等法律法规，以及本所《股票上市规则》 1 深 圳 证 券 交 易 所 及相关规定，真实、准确、完整、及时、公平地履行信息披露义 务，杜绝此类事件发生。 特此函告 深圳证券交易所 上市公司管理一部 2 ...

Financial Performance - The company reported a cash dividend of 6.00 RMB per 10 shares, based on a total of 616,481,927 shares[40]. - Xiamen Jindawei Group reported a revenue of 1.2 billion RMB for the fiscal year 2021, reflecting a year-on-year growth of 15%[47]. - The company achieved a net profit of 200 million RMB, representing an increase of 10% compared to the previous year[47]. - The company's operating revenue for 2021 was CNY 3,616,159,485.95, representing a 3.19% increase compared to CNY 3,504,406,641.70 in 2020[159]. - The net profit attributable to shareholders for 2021 was CNY 788,857,879.79, a decrease of 17.76% from CNY 959,207,761.32 in 2020[159]. - The net cash flow from operating activities for 2021 was CNY 847,331,118.18, a decline of 12.45% compared to CNY 967,849,312.92 in 2020[159]. - Basic earnings per share for 2021 were CNY 1.29, down 17.83% from CNY 1.57 in 2020[159]. - The weighted average return on net assets for 2021 was 21.67%, a decrease of 8.55% from 30.22% in 2020[159]. - Total assets at the end of 2021 reached ¥5,847,967,344.97, an increase of 13.49% compared to the end of 2020[161]. - Net assets attributable to shareholders of the listed company were ¥3,970,556,485.97, reflecting a growth of 15.81% year-over-year[161]. Market and Competitive Landscape - The competitive landscape in the health supplement industry is intensifying, with pressures from both domestic and international competitors affecting market positioning[15]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[47]. - The global consumer health products market reached $273.24 billion in 2021, with China holding a market share of 17.76%[176]. - The company expects the Chinese consumer health products market to grow to $62.40 billion by 2025, maintaining a growth rate of over 6%[176]. Product Development and Innovation - Investment in R&D increased by 20%, focusing on innovative health products and technologies[47]. - New product launches include a line of dietary supplements projected to generate 300 million RMB in sales within the first year[47]. - The strategic partnership with international brands is anticipated to contribute an additional 150 million RMB in revenue over the next two years[47]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 500 million RMB allocated for this purpose[47]. Environmental Protection and Compliance - Jin Dawei Pharmaceutical invested CNY 17.17 million in environmental protection during the reporting period[75]. - Chengxin Pharmaceutical invested CNY 7.20 million in environmental protection during the reporting period[76]. - Jin Dawei Vitamin's wastewater treatment facility has a processing capacity of 250 m³/d after upgrades[76]. - Jin Dawei Vitamin achieved 100% operational efficiency for automatic monitoring of wastewater parameters[86]. - The company emphasizes its commitment to environmental protection and has implemented energy-saving and emission-reduction initiatives[94]. - The company’s environmental protection measures have been effective, as all reported emissions are within the regulatory limits[118]. - The company achieved compliance with wastewater discharge standards, with COD levels at 22.1 mg/L and ammonia nitrogen at 5.43 mg/L[128]. Risk Management - The company faces significant risks from exchange rate fluctuations, particularly as overseas sales constitute a large portion of total revenue[32]. - The company warns investors about stock market volatility influenced by various external factors, including macroeconomic conditions[20]. - The company acknowledges the potential for goodwill impairment due to acquisitions if the acquired companies' performance deteriorates[19]. - The company employs hedge accounting to manage risks associated with financial instruments, ensuring effective risk management strategies[136]. Human Resources and Corporate Governance - The total number of employees at the end of the reporting period is 2,409, with 1,062 in production, 479 in sales, and 195 in technical roles[57][59]. - The company has established a robust corporate governance structure to protect shareholder and creditor rights, ensuring fair and accurate information disclosure[127]. - The company has committed to maintaining the rights and interests of all shareholders and ensuring fair treatment in stock issuance and other financial activities[142]. - The company has established a scientific compensation management system and incentive mechanism to attract and retain talent[156]. Social Responsibility - The company donated CNY 15,000 to support impoverished students at a local school[130]. - Jin Dawei's long-term poverty alleviation efforts have successfully led to the overall poverty alleviation of targeted villages[131]. - The company is focused on creating a harmonious development environment, balancing corporate growth with social responsibility[94].